Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 652 Download: 53

Review

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 1085 Download: 145

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 665 Download: 96

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 544 Download: 40

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 834 Download: 73

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 3740 Download: 92 Citation: 1

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 1884 Download: 203

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 977 Download: 150 Citation: 1

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 543 Download: 87

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 706 Download: 96

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 765 Download: 103

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 1073 Download: 113

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 618 Download: 62

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 1024 Download: 114 Citation: 1

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 763 Download: 96

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 912 Download: 84

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 894 Download: 109 Citation: 1

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 1004 Download: 180

Correspondence

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

View: 766 Download: 22

Letter to the Editor

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

View: 834 Download: 37

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

View: 787 Download: 31

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 940 Download: 32 Citation: 1

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0326

View: 1017 Download: 40 Citation: 1

Review

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 2698 Download: 328 Citations: 2

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 1865 Download: 155 Citations: 2

Snapshot

Personalized medicine in nonalcoholic fatty liver disease

Carlos J. Pirola, Silvia Sookoian

Clin Mol Hepatol. 2022;28(4):935-938. Published online June 24, 2022

DOI: https://doi.org/10.3350/cmh.2022.0175

View: 1635 Download: 104

Letter to the Editor

Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(4):933-934. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0267

View: 1203 Download: 45

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies

Li-Yu Lu, Min-You Wu, Yung-Shuo Kao, Cheng-Hsien Hung

Clin Mol Hepatol. 2022;28(4):931-932. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0259

View: 1231 Download: 71 Citations: 2

Original Article

COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Ka Shing Cheung, Chiu Hang Mok, Xianhua Mao, Ruiqi Zhang, Ivan FN Hung, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2022;28(4):890-911. Published online June 3, 2022

DOI: https://doi.org/10.3350/cmh.2022.0087

View: 2391 Download: 141 Citations: 6

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways

Seung Min Lee, Dong Hee Koh, Dae Won Jun, Yoon Jin Roh, Hyeon Tae Kang, Ju Hee Oh, Hyun Sung Kim

Clin Mol Hepatol. 2022;28(4):827-840. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0068

View: 2921 Download: 218 Citations: 4

1 | 2 | 3 | 4 | 5 |

Viewed By 5609	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Viewed By 3574	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 3244	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 2698	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2606	The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology

Cited By 88	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 40	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 36	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 34	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 33	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Search